Functionally, SLC27A5 deficiency leads to increased lipid peroxidation, activating the NRF2/TXNRD1 pathway, which contributes to tumour progression and resistance to therapies like sorafenib [283,284]. Here, SLC27A5 is linked to neoplasm.